Enhancing Lives Together

Comidamed and Mevalia Update from Vitaflo

 

Vitaflo acquired the Comidamed and Mevalia brands in 2021 as part of our commitment to enhance the lives of people with inborn errors of metabolism (IEM), wherever they are in the world. We have worked hard to integrate these brands into our Vitaflo family, despite very challenging global economic conditions, with our primary objective delivering consistent and reliable supply of high-quality products for your patients in the long term.

We’re investing in the future

We are excited to announce our plans for a multi-million euro investment in our Vitaflo production site in Germany which should be completed in 2025. This will create a state of the art, production facility to meet the highest standards required to produce specialist infant formula and protein substitutes for a range of IEMs in cans.

What to expect from us going forward

We would like to share with you the next phase of our plans for the Comidamed and Mevalia ranges. Products that we cannot guarantee continuity of supply, have outdated nutritional profiles, that duplicate products in our range or have very little demand, will be gradually removed. Our local teams will update you on any decisions that impact you and your patients. This will allow the range to remain simple and easy to navigate and allows us to focus on improving the products that are most popular with your patients and dedicating more resources to product innovation.

We are pleased to confirm that;

  • Comidamed, PKU Balance and PKU GMPower will continue to be options for your patients. Whilst we will move away from producing these in sachets, they will be available in a tin/can powder format, maintaining flexibility on dosing to meet your patient requirements.
  • PKU GMPower will be available in a tin/can in both Piña colada and Vanilla flavours.
  • PKU Motion will continue as part of Vitaflo’s extensive ready-to-drink range.

Over the coming months and years, these products will benefit from improvements to the nutritional profile, the introduction of sustainable packaging, and a 'new look' to reflect these changes.

  • We remain committed to the Mevalia low protein foods that are most popular with patients and any further changes to the range will be communicated at the earliest opportunity.

Our future

Comidamed, PKU Balance, PKU Motion, PKU GMPower and Mevalia low protein foods will form part of an exciting future for Vitaflo and be integral to our commitment to support patients with inborn errors of metabolism across the globe.​ We thank you for your ongoing cooperation and we look forward to moving to the next phase of this journey and updating you in good time as these changes happen. As always, we are committed to supporting you in enhancing patients' lives together.

 

About Nestlé Health Science and Vitaflo (International) Limited

Nestlé Health Science, a leader in the science of nutrition, is a globally managed business unit of Nestlé. We are committed to redefining the management of health, offering an extensive portfolio of science-based consumer health, medical nutrition, pharmaceutical therapies, and vitamin and supplement brands. Our extensive research network provides the foundation for products that empower healthier lives through nutrition. Headquartered in Switzerland, we have more than 7,000 employees around the world, with products available in more than 140 countries. www.nestlehealthscience.com

Vitaflo is a business unit of Nestlé Health Science with a global footprint. For over 20 years, Vitaflo has been at the forefront of developing innovative specialised clinical nutrition products for Inborn Errors of Metabolism, nutrition support and disease specific conditions.


Media contact:

Vitaflo (International) Limited

Olivia Lloyd

Tel: +44 (0) 151 709 9020

E-Mail: olivia.lloyd@vitaflo.co.uk